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ADULT CARDIAC SURGERY DURING COVID-19 PANDEMIC  
 




Coronavirus Disease 2019 (COVID-19), which is caused by the SARS Coronavirus 2 
(SARS-CoV-2), has affected over 200 countries worldwide. First case of COVID-19 was 
found in Wuhan, China, precisely around December 2019. COVID-19, especially in those 
with underlying health conditions or comorbidities, has an increasingly rapid and severe 
progression, often leading to death. This virus is a single-strand RNA coronavirus, binding the 
angiotensin-converting enzyme 2 (ACE2) receptor which enters human cells. Coronavirus 
disease has been reported to affect cardiac and vascular organs. cardiomyocyte death and 
inflammation are results of a direct mechanism that involves viral infiltration into myocardial 
tissue. Some cardiovascular manifestations of myocardial injuries associated with COVID-19 
are arrhythmias, myocardial infarction, heart failure, and elevated biomarkers (cardiac 
troponin I and brain-type natriuretic peptide). Some of this manifestation requires immediate 
intervention or surgery. Criteria are needed for hospitals or institutions that mostly maintain 
cardiac surgery services and surgery-urgent patients depending on severity of the disease and 
hospital resources. These criteria also limit the risk of exposure to patients and healthcare 
workers and allocate resources appropriately to those in greatest need. This paper aims to 
share our discussion and give an overview of patients undergoing cardiac surgery, providing 
clinicians with recommendations to triage and plan these procedures during the COVID-19 
outbreak effectively. 
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The ongoing global pandemic 
caused by Coronavirus Disease 2019 
(COVID-19), which is caused by the SARS 
(Severe Acute Respiratory Syndrome) 
Coronavirus 2 (SARS-CoV-2), has affected 
over 200 countries worldwide.1 The first 
case of COVID-19 was reported in Wuhan, 
China, precisely around December 2019.2 
On March 2nd, 2020, the Ministry of Health 
in Indonesia confirmed the first case of 
COVID-19 disease. As of August 23rd, 
2020, Indonesia had 153.535 confirmed 
cases of COVID-19, the highest in 
Southeast Asia. In terms of death numbers, 
Indonesia ranks ninth in Asia, with 6.680 
deaths with a case fatality rate of 4.35%.3 
This virus is a single-strand RNA 
coronavirus, which enters human cells 
mainly by binding the angiotensin-
converting enzyme 2 (ACE2) receptor.4 
Receptor downregulation happens after the 
virus binds with ACE2 and enters the cell, 
which is supposed to be the host's defense 
mechanism to limit further viral invasion to 
escape the immune system.5 The 
downregulation of ACE2 leads to 
decreased ANG1-7 level and increased 
ANG2 level. Physiologically, ANG2 can 
cause vasoconstriction, aldosterone 
secretion, increase inflammation and ROS 
(Reactive Oxygen Species) production, 
thrombosis, and fibrosis; simultaneously, 
ANG (Angiopoietin) 1-7 can be classified 
as a regulatory enzyme that contradicts the 
effect of ANG2 and becomes 
cytoprotective (e.g., anti-fibrosis and anti-
inflammation). This condition may induce 
uncontrollable cytokine storm and could 
lead to organ dysfunction in critical cases.6 
Respiratory tract symptoms largely 
characterize the clinical manifestation of 
SARS-CoV-2 infection, including fever, 
dry cough, dyspnea, myalgia, fatigue, and 
most frequently presents with respiratory 
symptoms. These symptoms most likely 
progress to pneumonia, and in some cases, 
might become acute respiratory distress 
syndrome and shock. However, some 
patients may present with non-specific 
cardiac manifestation.2,7,8 COVID-19, in 
those with underlying health conditions or 
comorbidities, has an increasingly rapid 
and severe progression, often leading to 
death.9 The outcomes after COVID-19 
infection might get worse on patients with 
risk factors such as old age, cardiovascular 
diseases (e.g., hypertension, coronary 
disease, or cardiomyopathy), diabetes, and 
chronic kidney disease.10 In Indonesia, the 
first comorbidity that patient had 
confirmed COVID-19 positive is 
hypertension, and the third is 
cardiovascular disease.3  All necessary 
precautions to avoid getting infected with 
COVID-19 should be taken by patients 
with comorbidity, as they usually have the 
 




worst prognosis.9 The Medical Association 
Indonesian General Surgery Specialist 
(“Persatuan Dokter Spesialis Bedah Umum 
Indonesia” in Indonesian or PABI) has also 
published work guidelines for all members 
of PABI in Indonesia for performing 
surgical services, including restrictions on 
visits to the surgical clinic and postponing 
surgical procedure. Prior to surgery, pre-
operative assessments were conducted to 
identify patients' risk, followed by 
necessary procedure adjustment. As an 
example, surgery-urgent patients with clear 
symptoms of clinical pneumonia or 
COVID-19 rapid test with reactive result 
will be treated as a patient with supervision 
use of PPE (Personal Protective 
Equipment) level 3.11,12 
The Society of Cardiothoracic 
Surgeons published criteria for hospitals or 
institutions that maintain cardiac surgery 
services and surgery-urgent patients.13 
Patients with a state of emergency that 
need immediate surgery are the ones with 
the acute coronary syndrome unsuitable for 
percutaneous intervention, ascending aortic 
dissection, acute valvular endocarditis, and 
heart failure patients expecting a heart 
transplant.	 Patients with such conditions 
cannot be discharged without a definitive 
procedure (e.g., severe coronary artery 
disease, symptomatic critical aortic 
stenosis, progressive angina, aortic 
aneurysm at risk based on size and 
familialassociation, cardiac tumors at risk 
of obstruction or embolization, and patients 
with correctable, anatomic causes of heart 
failure).14 This paper aims to share our 
discussion and give an overview of patients 
undergoing cardiac surgery, providing 
clinicians with recommendations to triage 
and plan these procedures during the 
COVID-19 outbreak effectively. This 
guidance will help limit the risk of 
exposure to patients and healthcare 
workers and allocate resources 
appropriately to those in greatest need.  
 
2. CARDIAC AND VASCULAR 
MANIFESTATION IN COVID-19 
PATIENTS 
The mechanisms of cardiac injury 
from COVID-19 are not well established 
but likely can result in direct or indirect 
mechanisms. The cardiomyocyte death and 
inflammation results from a direct 
mechanism that involves viral infiltration 
into myocardial tissue. Indirect 
mechanisms include cardiac stress due to 
respiratory failure and hypoxemia and 
cardiac inflammation secondary to severe 
systemic hyper inflammation.15 The 
manifestations of myocardial injury are 
arrhythmias, myocardial infarction, heart 
failure, and elevating biomarkers (cardiac 
troponin I and brain-type natriuretic 
peptide). Increased troponin level 
 




represents evidence of myocardial injury, 
and these may come from cytokine storm, 
hypoxic injury, coronary spasm, micro 
thrombin, myocarditis, or actual plaque 
rupture.16,17 The HFpEF indicates heart 
failure with preserved ejection fraction, 
HFrEF, heart failure with minimized 
ejection fraction, and SARS-CoV-2, severe 
acute respiratory syndrome novel 
coronavirus.15 Although the respiratory 
tract is the primary target for SARS-CoV-
2, the Cardiovascular system may get 
involved in a few different ways.18 The 
following are the common Cardiovascular 
disease associated with COVID-19. (table 
1)  
 
Table 1. Guidance from each cardiovascular presentation of COVID-19 (Adapted and 
Modified from 8, 19,20,21) 
COVID 19 Associated Cardiovascular Disease 
ST Segment 
Elevation 
- Myo-pericarditis should be considered in patients with chest pain, ECG changes, 
and biomarker elevation. Maintain a low threshold to assess for cardiogenic shock 
in this setting. 
- Use bedside TTE and possibly CCTA to triage cases before cardiac catheterization, 
consider a conservative strategy in appropriately selected cases. 
- Consider bedside pulmonary artery catheterization and bedside IABP placement. 
IABP might be the preferred device for a cardiogenic shock as an effect of lower 
management requirements. 
- Even most of the clinical presentation is dominated by cardiac manifestations, and 
there is no fever, COVID-19 should be in the differential.   
Cardiogenic Shock 
- Myocardial dysfunction might be caused by direct mechanism injury by virus or 
secondary to cytokine storm. 
- ECMO provides circulatory (VA) and respiratory support (VV). Low flows on VA 
ECMO may be sufficient. 
- Stabilization and recovery of profound cardiac dysfunction related to COVID-19 
are viable with temporary mechanical circulatory support. 
- ECMO requires high resource utilization and should be appropriately used during 
the COVID-19 pandemic. 
Arrhythmias 
- In addition to blood pressure abnormalities, patients can also develop arrhythmias, 
ranging from tachycardia and bradycardia to asystole. 
- That cardiac arrhythmia was reported significantly more common in patients with 
critical forms of COVID-19 
- Arrhythmias can arise just second to hypoxemia, metabolic derangements, systemic 
inflammation, or myocarditis. 
- Amiodarone, a widely used antiarrhythmic drug, has been shown to inhibit the 
SARS coronavirus's in vitro spreading. 
Decompensated 
Heart Failure 
- Preexisting HF with diastolic dysfunction or chronically elevated end diastolic 
pressures who develop capillary leak, might be exacerbated by COVID-19. 
- Invasive hemodynamic management and achievement of euvolemia monitoring 
might be valuable in some cases to manage both cardiac and respiratory failure.  
- The use of QT-prolonging agents (azithromycin, hydroxychloroquine) should be 
nearly monitored in patients with underlying cardiomyopathies. 
CCTA indicates cardiac computed tomographic angiography; COVID-19, coronavirus disease 
2019; ECMO, extracorporeal membrane oxygenation; IABP, Intra aortic balloon pump; TTE, 
transthoracic echocardiogram; VA, veno-arterial; and VV, venovenouw
 





Most of the latest reports on 
COVID-19 have only shortly described 
Cardiovascular manifestations in these 
patients. The poor prognosis of COVID-19 
indicated by altered biomarkers, including 
troponin, natriuretic peptides, and 
coagulation parameters, reflects cardiac 
injury and stress. Adverse effects of 
various therapies, various antiviral drugs, 
corticosteroids, and other therapies aimed 
at treating COVID-19 can also have 
deleterious effects on the Cardiovascular 
system.18 Given the enormous burden 
posed by this illness and the significant 
adverse prognostic impact of cardiac 
involvement, further research is required to 
understand the incidence, mechanisms, 
clinical presentation, and outcomes of 
various Cardiovascular manifestations in 
COVID-19 patients. Besides that, intensive 
monitoring of these biomarkers could help 
early detections of cardiac injury and 
possibly prevent further decline with 
appropriate management if available. 
 
3. TIMING OF CARDIAC SURGERY 
INTERVENTION ON CASE TYPE 
AND URGENCY CATEGORY 
 During this pandemic, hospital 
resources divide three phases of handling 
patients. The division of three phases was 
carried out, aiming to determine the 
operating decisions taken based on the 
level of emergency and urgency. This 
division is also carried out considering that 
each hospital has the policy to reduce 
operations number by up to 30%, while the 
increase only depends on the phase.13,22,23 
Therefore, operations classified as elective 
should be postponed, and only work on 
emergency and urgent cases. Emergency 
cases are more comfortable to determine, 
and intervention should be undertaken 
immediately to reduce mortality. Whereas 
in urgent cases, intervention does not have 
to be done immediately, but surgery must 
be done within 1-2 weeks. In semi-
emergency cases, surgery should be 
performed within of 2-4 weeks.13,24 
Whereas in elective cases, surgery can be 














Table 2. Timing of cardiac surgery intervention depending on case type and urgency 
category (Adapted from25 ) 
 
Category timing Emergent immediate 







CAD (not amenable 
to PCI) 
• Critical CAD/LM ± 
shock/IABP/pressors 
• LM, ACS or w/3VD 
with high-risk 
anatomy 
• 3VD w/ increasing 
Sx 
• Stable CAD 
AV (not amenable 
to TAVR) 
• Severe AI w/shock 
• Severe AS w/shock 
• Severe AI/AS 
w/NYHA IV HF, 
syncope 
• BHV SVD w/NYHA 
IV HF 




• Progressive severe 
Al with progressice 
Sx 
• Stable severe 
AI/AS 
MV disease (not 
amenable to MC) 
• Acute MR w/shock • Acute MR with 
NYHA IV HF 
• BHV SVD w/NYHA 
IV HF 
• Severe MR w/drop 
in EF recurrent HF 
• MS with NYHA 
III-IV HF 




• NA • NA • NYHA IV Sx • Stable severe TR 
Aortic surgery / 
other 
• Type A dissection 
• PTE w/massive dot 
• Giant TAA/PSA w/Sx 
or rapid expansion 
• TAA >6-7 cm • Stable TAA 
• PTE for CTEPH 
Transplant • NA • Inpatient + status 1-2 • NA • Stable outpatient 
 
 Cases classified as elective should 
be postponed as long as possible. The 
postponed surgery in this elective case 
aims to prevent COVID-19 infection 
during the operation period. The presence 
of COVID-19 infection in heart surgery 
cases shows a high mortality rate. A study 
by Lei et al. in Wuhan, China, on 34 
patients with heart surgery in the early 
phases of the pandemic showed COVID-19 
infection in all patients. As many as 44% 
of patients in the study required ICU 
admission, resulting in the mortality rate of 
20.5%. The causes of death included in the 
study were ARDS, shock, arrhythmias, and 
acute cardiac injury.2 It is also necessary to 
watch out for patients with old age and 
patients with comorbid diseases. 
Regardless of these categorizations of  
 
emergencies and urgency, cardiac surgeons 
should carry out close monitoring of 
patients whose surgery is delayed. The 
progression of the patient's disease should 
be noted while waiting for surgery. George  
et al., in their literature review, 
recommended one consultation per week 
for monitoring. The classification of 
emergencies and urgencies is also carried 
out based on the organs involved, namely 
the coronary, atrial valves, mitral valves, 
tricuspid valves, and aorta.14,26 
 As mentioned before, the phases of 
patient handling during the COVID-19 
pandemic are divided into three. In phase 
1, COVID-19 positive patients are 0-30% 
(Table 3) of the total patients, reduction in 
the number of surgeries at the mild level, 
with sufficient ICU and ventilator capacity. 
 




In phase 2, COVID-19 patients account for 
30-60% of total hospital patients (Table 
4).27 The reduction in the number of 
surgeries was at a moderate level. There 
are limitations to the ICU, ventilators, 
medical personnel, and PPE facilities in 
this phase. In phase 3, COVID-19 patients 
account for >60% of the total patients in 
the hospital (Table 5). The reduction in the 
number of surgeries is at a severe level. In 
this phase, the ICU, ventilators, medical 
personnel, and PPE are critical, so that only 
emergency operations are carried out.13 
Table 3. Phase 1 of Cardiac Surgery Patient Handling During COVID-19 Pandemic 
(Adapted from13) 
Phase 1 
Essential services Deferred 
• All inpatients waiting for surgery, including 
emergency services (i.e., ascending aortic 
dissections, acute coronary syndromes, acute 
valvular endocarditis, and heart failure patients 
awaiting a heart transplant or VAD) 
• Outpatients who are at most significant risk of 
adverse event, examples of which include: 
o Symptomatic critical aortic stenosis 
o CAD 
o Severe CAD with the large territory of 
myocardium at risk 
o Asymptomatic CAD with reduced systolic 
function 
o Progressive angina 
o Cardiac tumors at risk of obstruction or 
embolization 
o Aortic aneurysm at risk based on size and 
familial association 
o Patients with correctable, anatomic causes of 
heart failure (valvular or myocardial; i.e., HCM, 
adult congenital) 
End-stage heart failure patients in evaluation for 
mechanical assist devices which are inotrope 
dependent 
• Asymptomatic outpatients 
• Truly elective intervention could include: 
o Asymptomatic or minimally symptomatic 
severe MR 
o ASD or PFO surgery or both 
o Asymptomatic aneurysm with demonstrated 
stable size 
o Isolated arrhythmia procedures 
• Programs are encouraged to adopt a mechanism by which patients can be screened regularly in order to 
identify those having increased symptoms or progression of the disease 
• Transcatheter interventions will follow the same recommendations 
• Alterntive precutaneous therapies with rapid discharge from the hospital should be considered 
• Thoracic organ transplant guidance is provided by the United Network for Organ Sharing 
VAD, Ventricular assist device; CAD, coronary artery disease; HCM, hypertrophic 

















Table 4. Phase 2 of Cardiac Surgery Patient Handling During COVID-19 Pandemic 
(Adapted from13) 
Phase 2 
Essential services Deferred 
• All inpatients waiting for surgery, 
including emergency services  
• Outpatients with progressive symptoms 
who have demonstrated a failure to medical 
management 
o Symptomatic CAD 
• Asymptomatic CAD with impaired systolic 
function 
• Asymptomatic outpatients and patients 
with anatomy and physiology suggesting 
delay can be provided with reasonable 
safety 
 
• Programs are encouraged to adopt a mechanism by which patients can be screened 
regularly in order to identify those with increased symptoms  
• Transcatheter interventions will follow the same recommendations 
• Alternative percutaneous therapies with rapid discharge from the hospital should be 
considered 
 
Table 5. Phase 3 of Cardiac Surgery Patient Handling During COVID-19 Pandemic 
(Adapted from13) 
Phase 3 
Essential services Deferred 
• All inpatients who cannot be discharged 
safely without surgical 
intervention/correction, including 
emergency services 
• All patients who are outpatients 
• Patients deteriorating while waiting would 
need to meet criteria for admission before 
consideration for surgery 
 
• Programs are encouraged to adopt a mechanism by which patients can be screened 
regularly in order to identify those with increased symptoms  
• Transcatheter interventions will follow the same recommendations 
• Alternative percutaneous therapies with rapid discharge from the hospital should be 
considered 
• The United Network provides thoracic organ transplant guidance for Organ Sharing 
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